Answers are grounded in this paper and cite their sources.
Drug-induced muscle dysfunction represents a significant and perhaps increasing subset of neuromuscular disorders that face the clinician. Whereas severe symptoms of proximal weakness and elevated muscle enzymes in an uncomplicated patient taking a single medication may lead to straightforward diagnosis, the tendency for patients with multisystem disease, on multiple medications, with multiple potential causes for weakness makes the diagnosis of toxic myopathy challenging. Furthermore, many toxic myopathies are characterized by nonspecific clinical and laboratory findings, ultimately requiring a trial of drug discontinuation in order to clarify the diagnosis. This review summarizes recent observations with regard to toxic effects on neuromuscular transmission and toxic myopathies.
No takes yet. Share an insight, caveat, or question.
Robert M. Pascuzzi (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: